preview
Advertisement This month I have the pleasure of interviewing Caroline Baumal, who is professor of Ophthalmology at Tufts University in Boston, MA. Caroline…
Related Articles
Alcon to Acquire LumiThera
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
In Memoriam: Jerry A. Shields, MD
A founder of modern ocular oncology, Dr. Shields helped transform eye cancer care through innovation, research, and mentorship. The retina community mourns the passing of…
Remote OCT Protocol to Speed Diagnosis and Treatment of CRAO
Remote diagnosis of CRAO can reduce the time to treatment for eligible patients and therefore increase the chance of visual recovery. A novel clinical diagnostic…
FDA Greenlights Ocugen’s Pivotal Stargardt Trial
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
AI-READI: A Multimodal Data Set for Diabetic Eye Research
The Artificial Intelligence-Ready Exploratory Atlas for Diabetes Insights (AI-READI) project aims to fill a critical gap in the lack of large, well-curated structured data sets…
Retinal Physician June 2025
JUNE 2025 VOLUME 22 | NUMBER 5 www.retinalphysician.com The Effect of GLP-1RAs in Diabetic Retinopathy JULIA H. JOO, MD, MPH • ALEKSANDRA V. RACHITSKAYA, MD…
History and Current Directions of the DRCR Retina Network
Learn about the impactful work of the DRCR Retina Network in improving treatments for retinal diseases, including diabetic macular edema and proliferative diabetic retinopathy.
OCT Biomarkers Predict Anti-VEGF Failure in DME
Specific optical coherence tomography (OCT) biomarkers can significantly predict the likelihood of treatment failure with anti-VEGF agents in patients with diabetic macular edema (DME), according…
Clinical Trial Update June 2025
Access Retinal Physician’s listing of all active clinical trials in AMD, DME, RVO, and uveitis.